leuprolide acetate for depot suspension

P2, N=40, Recruiting, Icahn School of Medicine at Mount Sinai | Trial primary completion date: Dec 2026 --> Dec 2027

The patient had undergone laparoscopic radical prostatectomy 5 years prior and received intermittent postoperative endocrine therapy with leuprorelin acetate and bicalutamide...Following a change in the endocrine therapy regimen to rezvilutamide combined with degarelix, the patient's hematuria significantly improved. This case highlights the critical importance of rigorous postoperative surveillance and timely, standardized endocrine therapy in prostate cancer management. It also contributes to the limited literature on visceral metastases in castration-sensitive prostate cancer (HSPC) and underscores the need for further exploration of optimal treatment strategies for advanced metastatic disease.

She received bromocriptine (up to 5 mg/day) for 6 months without response. Clinicians should consider extrapituitary prolactin-secreting lesions in patients with treatment-refractory hyperprolactinemia. Genetic evaluation may further elucidate the pathogenesis of such rare entities.

P1/2, N=55, Not yet recruiting, Novartis Pharma AG

P=N/A, N=1905, Completed, Takeda | Recruiting --> Completed

P4, N=500, Recruiting, Azienda Ospedaliero Universitaria Di Modena | Not yet recruiting --> Recruiting

P1/2, N=100, Not yet recruiting, University of Illinois at Chicago

P1/2, N=55, Not yet recruiting, Novartis Pharma AG | N=26 --> 55

P1/2, N=102, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: May 2027 --> May 2029 | Trial primary completion date: Nov 2026 --> May 2027

P=N/A, N=94, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Apr 2027

Brain metastases from prostate cancer with elevated CEA and CA19-9 are rare. Although these markers often indicate a poor prognosis, this patient achieved a favorable outcome with multimodal treatment. https://thejns.org/doi/10.3171/CASE25735.

P3, N=315, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2027 --> Sep 2028